Mazzeo Anna Teresa, Alves Oscar Luís, Gilman Charlotte B, Hayes Ronald L, Tolias Christos, Niki Kunene K, Ross Bullock M
Department of Neuroscience, Psychiatric and Anesthesiological Sciences, University of Messina, Viale Regina Margherita n. 59, 98121 Messina, Italy.
Acta Neurochir (Wien). 2008 Oct;150(10):1019-31; discussion 1031. doi: 10.1007/s00701-008-0021-7. Epub 2008 Sep 9.
Mitochondrial dysfunction is a major limiting factor in neuronal recovery following traumatic brain injury. Cyclosporin A (CsA) has been recently proposed for use in the early phase after severe head injury, for its ability to preserve mitochondrial bioenergetic state, potentially exerting a neuroprotective effect. The aim of this study was, therefore, to evaluate the effect of CsA on brain energy metabolism, as measured by cerebral microdialysis, and on cerebral hemodynamics, in a group of severely head injured patients.
Fifty adult patients with a severe head injury were enrolled in this randomized, double-blind, placebo-controlled study. Patients received 5 mg/kg of CsA over 24 h, or placebo, within 12 h of the injury. A microdialysis probe was placed in all patients, who were managed according to standard protocols for the treatment of severe head injury.
The most robust result of this study was that, over most of the monitoring period, brain dialysate glucose was significantly higher in the CsA treated patients than in placebo. Both lactate and pyruvate were also significantly higher in the CsA group. Glutamate concentration and lactate/pyruvate ratio were significantly higher in the placebo group than in CsA treated patients, respectively 1 to 2 days, and 2 to 3 days after the end of the 24-h drug infusion. The administration of CsA was also associated with a significant increase in mean arterial pressure (MAP) and cerebral perfusion pressure (CPP).
The administration of CsA in the early phase after head injury resulted in significantly higher extracellular fluid glucose and pyruvate, which may be evidence of a beneficial effect. The early administration of CsA was also associated with a significant increase in MAP and CPP and such a potentially beneficial hemodynamic effect might contribute to a neuroprotective effect.
线粒体功能障碍是创伤性脑损伤后神经元恢复的主要限制因素。环孢素A(CsA)最近被提议用于重度颅脑损伤后的早期阶段,因其能够维持线粒体生物能状态,可能发挥神经保护作用。因此,本研究的目的是评估CsA对一组重度颅脑损伤患者脑能量代谢(通过脑微透析测量)和脑血流动力学的影响。
五十名成年重度颅脑损伤患者被纳入这项随机、双盲、安慰剂对照研究。患者在受伤后12小时内接受24小时静脉输注5mg/kg CsA或安慰剂。所有患者均置入微透析探头,并按照重度颅脑损伤的标准治疗方案进行管理。
本研究最显著的结果是,在大部分监测期内,CsA治疗组患者脑透析液葡萄糖水平显著高于安慰剂组。CsA组的乳酸和丙酮酸水平也显著更高。在24小时药物输注结束后的1至2天和2至3天,安慰剂组的谷氨酸浓度和乳酸/丙酮酸比值分别显著高于CsA治疗组患者。给予CsA还与平均动脉压(MAP)和脑灌注压(CPP)显著升高有关。
颅脑损伤后早期给予CsA可使细胞外液葡萄糖和丙酮酸水平显著升高,这可能是有益作用的证据。早期给予CsA还与MAP和CPP显著升高有关,这种潜在的有益血流动力学效应可能有助于发挥神经保护作用。